Exelixis reported that its zanzalintinib (as the next franchise following Cabometyx) failed to hit a primary endpoint in a colorectal cancer trial while the FDA review continues. The setback adds uncertainty for the program’s regulatory path and underscores the difficulty of translating late-stage oncology concepts into definitive efficacy. Analyst commentary cited by the article suggested FDA approval could still remain possible, but the reported failure in primary efficacy reduces momentum for the program’s clinical narrative. The report frames the study outcome as a key event for Exelixis’ pipeline planning during an ongoing regulatory process. The development matters for companies weighing whether to reposition programs or adjust trial strategies when phase-to-registration signals diverge.